Inhibition of miR‑214 attenuates the migration and invasion of triple‑negative breast cancer cells

Zhang,Yi; Zhao,Zhijing; Li,Siqi; Dong,Liying; Li,Yan; Mao,Ying; Liang,Ying; Tao,Yun; Ma,Junfeng

doi:10.3892/mmr.2019.10112

Inhibition of miR‑214 attenuates the migration and invasion of triple‑negative breast cancer cells

Authors:
- Yi Zhang
- Zhijing Zhao
- Siqi Li
- Liying Dong
- Yan Li
- Ying Mao
- Ying Liang
- Yun Tao
- Junfeng Ma
View Affiliations

Affiliations: Thyroid‑Breast Surgery Department, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, P.R. China, Clinical Skill Center, Kunming Medical University, Kunming, Yunnan 650500, P.R. China
Published online on: April 1, 2019 https://doi.org/10.3892/mmr.2019.10112
Pages: 4035-4042
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple‑negative breast cancer (TNBC) is a subtype of breast cancer. MicroRNA (miR)‑214 is closely associated with controlling the development of tumor cells; therefore, in the present study, the target gene and effects of miR‑214 on TNBC cells were explored. Luciferase activity was examined by luciferase reporter assay. The viability, invasion and migration of MDA‑MB‑231 TNBC cells were measured using Cell Counting kit‑8, Transwell and wound‑healing assays, respectively. The expression levels of various factors were determined using reverse transcription‑quantitative polymerase chain reaction and western blotting. The results demonstrated that the expression levels of miR‑214 were higher and the levels of α1‑antitrypsin (α1‑AT) were lower in TNBC tissues compared with in normal tissues. Subsequently, α1‑AT was revealed to be a target of miR‑214. Furthermore, inhibition of miR‑214 decreased cell viability, invasion and migration, enhanced the expression of E‑cadherin and tissue inhibitor of metalloproteinases‑2, and reduced the expression of metastatic tumour antigen 1 and matrix metalloproteinase‑2. Inhibition of miR‑214 also significantly downregulated the phosphorylation of protein kinase B (Akt) and mammalian target of rapamycin (mTOR), and markedly downregulated that of phosphoinositide 3‑kinase (PI3K); however, the expression levels of total PI3K, Akt and mTOR remained stable in all groups. Taken together, these findings indicated that α1‑AT may be a target of miR‑214. Downregulation of miR‑214 markedly suppressed the viability, migration and invasion of MDA‑MB‑231 cells, and inhibited the PI3K/Akt/mTOR pathway. These findings suggested that miR‑214 targeting α1‑AT may be a potential mechanism underlying TNBC development.

View Figures

View References

1	Wu J, Goyal L, Nipp R, Wo J, Qadan M and Uppot RN: The Tipping Point: Key oncologic imaging findings resulting in critical changes in the management of malignant tumors of the gastrointestinal tract. Curr Probl Diagn Radiol. 48:61–74. 2019. View Article : Google Scholar : PubMed/NCBI
2	DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014. View Article : Google Scholar : PubMed/NCBI
3	Dunne M, Dou YN, Drake DM, Spence T, Gontijo SML, Wells PG and Allen C: Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer. J Control Release. 282:35–45. 2018. View Article : Google Scholar : PubMed/NCBI
4	Park IH, Kong SY, Kwon Y, Kim MK, Sim SH, Joo J and Lee KS: Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer. J Cancer. 9:1145–1151. 2018. View Article : Google Scholar : PubMed/NCBI
5	Zenzola V, Cabezas-Quintario MA, Arguelles M, Perez-Fernandez E, Izarzugaza Y, Correa A and Garcia-Foncillas J: Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer. Clin Transl Oncol. 20:1448–1454. 2018. View Article : Google Scholar : PubMed/NCBI
6	Farah M, Nagarajan P, Torres-Cabala CA, Curry JL, Amaria RN, Wargo J, Tawbi H, Ivan D, Prieto VG, Tetzlaff MT and Aung PP: Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. J Cutan Pathol. 45:545–549. 2018. View Article : Google Scholar : PubMed/NCBI
7	Hejduk B, Bobek-Billewicz B, Rutkowski T, Hebda A, Zawadzka A and Jurkowski MK: Application of Intravoxel Incoherent Motion (IVIM) model for differentiation between metastatic and non-metastatic head and neck lymph nodes. Pol J Radiol. 82:506–510. 2017. View Article : Google Scholar : PubMed/NCBI
8	Ma J, Yang Y, Huo D, Wang Z, Zhai X, Chen J, Sun H, An W, Jie J and Yang P: LincRNA-RoR/miR-145 promote invasion and metastasis in Triple-negative breast cancer via targeting MUC1. Biochem Biophys Res Commun. 500:614–620. 2018. View Article : Google Scholar : PubMed/NCBI
9	Kumar MS, Lu J, Mercer KL, Golub TR and Jacks T: Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 39:673–677. 2007. View Article : Google Scholar : PubMed/NCBI
10	Abdellatif M: Differential expression of microRNAs in different disease states. Circ Res. 110:638–650. 2012. View Article : Google Scholar : PubMed/NCBI
11	Pillai RS: MicroRNA function: Multiple mechanisms for a tiny RNA? RNA. 11:1753–1761. 2005. View Article : Google Scholar : PubMed/NCBI
12	Guo Y, Jiang Y, Sang M and Xu C: Down-regulation of miR-373 increases the radiosensitivity of lung cancer cells by targeting TIMP2. Int J Biochem Cell Biol. 99:203–210. 2018. View Article : Google Scholar : PubMed/NCBI
13	Li X, Zhao Z, Li M, Liu M, Bahena A, Zhang Y, Zhang Y, Nambiar C and Liu G: Sulforaphane promotes apoptosis, and inhibits proliferation and self-renewal of nasopharyngeal cancer cells by targeting STAT signal through miRNA-124-3p. Biomed Pharmacother. 103:473–481. 2018. View Article : Google Scholar : PubMed/NCBI
14	Liu X, He B, Xu T, Pan Y, Hu X, Chen X and Wang S: MiR-490-3p functions as a tumor suppressor by inhibiting oncogene VDAC1 expression in colorectal cancer. J Cancer. 9:1218–1230. 2018. View Article : Google Scholar : PubMed/NCBI
15	Polakovicova I, Jerez S, Wichmann IA, Sandoval-Borquez A, Carrasco-Veliz N and Corvalan AH: Role of microRNAs and exosomes in helicobacter pylori and epstein-barr virus associated gastric cancers. Front Microbiol. 9:6362018. View Article : Google Scholar : PubMed/NCBI
16	Shan X, Zhang H, Zhang L, Zhou X, Wang T, Zhang J, Shu Y, Zhu W, Wen W and Liu P: Identification of four plasma microRNAs as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China Med 7. 2370–2381. 2018.PubMed/NCBI
17	Wang Y, Bao W, Liu Y, Wang S, Xu S, Li X, Li Y and Wu S: miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1. Cell Death Dis. 9:4472018. View Article : Google Scholar : PubMed/NCBI
18	Zhang T, Liu W, Meng W, Zhao H, Yang Q, Gu SJ, Xiao CC, Jia CC and Fu BS: Downregulation of miR-542-3p promotes cancer metastasis through activating TGF-β/Smad signaling in hepatocellular carcinoma. Onco Targets Ther. 11:1929–1939. 2018. View Article : Google Scholar : PubMed/NCBI
19	Hu JL, He GY, Lan XL, Zeng ZC, Guan J, Ding Y, Qian XL, Liao WT, Ding YQ and Liang L: Inhibition of ATG12-mediated autophagy by miR-214 enhances radiosensitivity in colorectal cancer. Oncogenesis. 7:162018. View Article : Google Scholar : PubMed/NCBI
20	Kalniete D, Nakazawa-Miklasevica M, Strumfa I, Abolins A, Irmejs A, Gardovskis J and Miklasevics E: High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients. Hered Cancer Clin Pract. 13:72015. View Article : Google Scholar : PubMed/NCBI
21	Liu Y, Lin J, Zhai S, Sun C, Xu C, Zhou H and Liu H: MicroRNA-214 suppresses ovarian cancer by targeting β-Catenin. Cell Physiol Biochem. 45:1654–1662. 2018. View Article : Google Scholar : PubMed/NCBI
22	Wang X, Zhang H, Bai M, Ning T, Ge S, Deng T, Liu R, Zhang L, Ying G and Ba Y: Exosomes serve as nanoparticles to deliver anti-miR-214 to reverse chemoresistance to cisplatin in gastric cancer. Mol Ther. 26:774–783. 2018. View Article : Google Scholar : PubMed/NCBI
23	Chen X, Wang YW, Zhu WJ, Li Y, Liu L, Yin G and Gao P: A four-microRNA signature predicts lymph node metastasis and prognosis in breast cancer. Hum Pathol. 76:122–132. 2018. View Article : Google Scholar : PubMed/NCBI
24	Li HL, Liang S, Cui JH and Han GY: Targeting of GSK-3β by miR-214 to facilitate gastric cancer cell proliferation and decrease of cell apoptosis. Eur Rev Med Pharmacol Sci. 22:127–134. 2018.PubMed/NCBI
25	Liu J, Chen W, Zhang H, Liu T and Zhao L: miR-214 targets the PTEN-mediated PI3K/Akt signaling pathway and regulates cell proliferation and apoptosis in ovarian cancer. Oncol Lett. 14:5711–5718. 2017.PubMed/NCBI
26	Costa RLB, Han HS and Gradishar WJ: Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: A review. Breast Cancer Res Treat. 169:397–406. 2018. View Article : Google Scholar : PubMed/NCBI
27	Ramakrishnan V and Kumar S: PI3K/AKT/mTOR pathway in multiple myeloma: From basic biology to clinical promise. Leuk Lymphoma. 1-11:2018.
28	Simioni C, Martelli AM, Zauli G, Vitale M, McCubrey JA, Capitani S and Neri LM: Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update. J Cell Physiol. 233:6440–6454. 2018. View Article : Google Scholar : PubMed/NCBI
29	Du L, Li X, Zhen L, Chen W, Mu L, Zhang Y and Song A: Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway. Mol Med Rep. 17:7163–7169. 2018.PubMed/NCBI
30	Yeh YH, Hsiao HF, Yeh YC, Chen TW and Li TK: Inflammatory interferon activates HIF-1α-mediated epithelial-to-mesenchymal transition via PI3K/AKT/mTOR pathway. J Exp Clin Cancer Res. 37:702018. View Article : Google Scholar : PubMed/NCBI
31	Zhang H, Xu HL, Wang YC, Lu ZY, Yu XF and Sui DY: 20(S)-Protopanaxadiol-induced apoptosis in MCF-7 breast cancer cell line through the inhibition of PI3K/AKT/mTOR signaling pathway. Int J Mol Sci. 19(pii): E10532018. View Article : Google Scholar : PubMed/NCBI
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Method. 25:402–408. 2001. View Article : Google Scholar
33	Fan Y, Qian X and Zhang C: U/G SNP rs111904020 in 3′UTR of STAT3 regulated by miR-214 promotes hepatocellular carcinoma development in Chinese population. Tumour Biol. 37:14629–14635. 2016. View Article : Google Scholar : PubMed/NCBI
34	Kuninty PR, Bojmar L, Tjomsland V, Larsson M, Storm G, Ostman A, Sandstrom P and Prakash J: MicroRNA-199a and −214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor. Oncotarget. 7:16396–16408. 2016. View Article : Google Scholar : PubMed/NCBI
35	El-Akawi ZJ, Al-Hindawi FK and Bashir NA: Alpha-1 antitrypsin (alpha1-AT) plasma levels in lung, prostate and breast cancer patients. Neuro Endocrinol Lett. 29:482–484. 2008.PubMed/NCBI
36	Hamrita B, Chahed K, Trimeche M, Guillier CL, Hammann P, Chaieb A, Korbi S and Chouchane L: Proteomics-based identification of alpha1-antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas. Clin Chim Acta. 404:111–118. 2009. View Article : Google Scholar : PubMed/NCBI
37	García-Orad A, Arizti P, Durán L, Urcelay B and De Pancorbo MM: Alpha-1-antitrypsin phenotypes among breast cancer patients in the basque population. Hum Hered. 44:203–208. 1994. View Article : Google Scholar : PubMed/NCBI
38	Lópezárias E, Aguilarlemarroy A, Felipe JL, Morganvillela G, Mariscalramírez I, Martínezvelázquez M, Alvarez AH, Gutiérrezortega A and Hernándezgutiérrez R: Alpha 1-antitrypsin: A novel tumor-associated antigen identified in patients with early-stage breast cancer. Electrophoresis. 33:2130–2137. 2012. View Article : Google Scholar : PubMed/NCBI
39	Wang F, Lv P, Liu X, Zhu M and Qiu X: microRNA-214 enhances the invasion ability of breast cancer cells by targeting p53. Int J Mol Med. 35:1395–1402. 2015. View Article : Google Scholar : PubMed/NCBI
40	Zhang ZC, Li YY, Wang HY, Fu S, Wang XP, Zeng MS, Zeng YX and Shao JY: Knockdown of miR-214 promotes apoptosis and inhibits cell proliferation in nasopharyngeal carcinoma. PLoS One. 9:e861492014. View Article : Google Scholar : PubMed/NCBI
41	Xin R, Bai F, Feng Y, Jiu M, Liu X, Bai F, Nie Y and Fan D: MicroRNA-214 promotes peritoneal metastasis through regulating PTEN negatively in gastric cancer. Clin Res Hepatol Gastroenterol. 40:748–754. 2016. View Article : Google Scholar : PubMed/NCBI
42	Pieters T and van Roy F: Role of cell-cell adhesion complexes in embryonic stem cell biology. J Cell Sci. 127:2603–2613. 2014. View Article : Google Scholar : PubMed/NCBI
43	Che F, Xie X, Wang L, Su Q, Jia F, Ye Y, Zang L, Wang J, Li H, Quan Y, et al: B7-H6 expression is induced by lipopolysaccharide and facilitates cancer invasion and metastasis in human gliomas. Int Immunopharmacol. 59:318–327. 2018. View Article : Google Scholar : PubMed/NCBI
44	Aravindan S, Natarajan M, Herman TS and Aravindan N: Radiation-induced TNFalpha cross signaling-dependent nuclear import of NFκB favors metastasis in neuroblastoma. Clin Exp Metastasis. 30:807–817. 2013. View Article : Google Scholar : PubMed/NCBI
45	Li G, Li QS, Li WB, Wei J, Chang WK, Chen Z, Qiao HY, Jia YW, Tian JH and Liang BS: miRNA targeted signaling pathway in the early stage of denervated fast and slow muscle atrophy. Neural Regen Res. 11:1293–1303. 2016. View Article : Google Scholar : PubMed/NCBI
46	Zhao C, Sun W, Zhang P, Ling S, Li Y, Zhao D, Peng J, Wang A, Li Q, Song J, et al: miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway. RNA Biol. 12:343–353. 2015. View Article : Google Scholar : PubMed/NCBI